Table 3.

Effect of 12 weeks of supplementation with GCWB106 on changes of the Visual Analog Scale score in subjects with knee osteoarthritis.

		GCWB106	Placebo	P-value
		(n = 53)	(n = 57)	between Groups
		Mean ± SD	Mean ± SD
VAS	Baseline (Visit 2)	43.09 ± 8.32	42.86 ± 8.82	.935
(mm)	6 wk (Visit 3)	34.15 ± 10.07	39.21 ± 8.34
	CFB	−8.94 ± 7.96	−3.65 ± 4.87	P < .001
	P-value∗	P < .001	p < 0.001
	12 wk (Visit 4)	30.30 ± 9.92	36.77 ± 9.07
	CFB	−12.79 ± 10.97	−6.09 ± 6.95	P < .001
	P-value∗	P < .001	P < .001

The values in the table are expressed as mean values (with standard deviation, SD).

^∗Derived from paired t-tests performed for values obtained at baseline and after the trial. CFB = changes from baseline, VAS = visual analog scale.